Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.

Eur J Pharmacol

New Product Research Laboratories II, Tokyo R & D Center, Daiichi Pharmaceutical Co. Ltd., 16-13, Kita-kasai 1-chome Edogawa-ku, Tokyo 134-8630, Japan.

Published: May 2005

We compared the antithrombotic properties of a factor Xa inhibitor (DX-9065a) with those of a thrombin inhibitor (melagatran) in a rat disseminated intravascular coagulation model and a rat venous thrombosis model. Rat disseminated intravascular coagulation and venous thrombosis models were produced by injection of tissue factor and platinum wire placement, respectively. DX-9065a exerted antithrombotic effects dose dependently in both models. Melagatran was also effective in the venous thrombosis model, whereas it showed an aggravation in the disseminated intravascular coagulation model at low but not high doses. In the in vitro study, DX-9065a decreased the C(max) of the thrombin generation curve in plasma irrespective of whether protein C was present or not. However, melagatran increased the C(max) at low concentrations when protein C was present. This increase was not detected in protein C-deficient plasma. These results suggest that, unlike DX-9065a, melagatran in low doses aggravates disseminated intravascular coagulation by increasing thrombin generation, which may be partly due to suppression of negative feedback by activated protein C.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2005.03.009DOI Listing

Publication Analysis

Top Keywords

disseminated intravascular
16
intravascular coagulation
16
venous thrombosis
12
antithrombotic properties
8
properties factor
8
factor inhibitor
8
thrombin inhibitor
8
thrombosis models
8
rat disseminated
8
coagulation model
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!